Is single anastomosis duodenoileal bypass (SADI) an effective option for conversional surgery following sleeve gastrectomy? A comprehensive review and revised scope of current literature

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Obesity research & clinical practice Pub Date : 2025-01-01 DOI:10.1016/j.orcp.2025.01.005

Ana Marta Pereira , Sofia S. Pereira , Mariana P. Monteiro , Marta Guimarães

{"title":"Is single anastomosis duodenoileal bypass (SADI) an effective option for conversional surgery following sleeve gastrectomy? A comprehensive review and revised scope of current literature","authors":"Ana Marta Pereira , Sofia S. Pereira , Mariana P. Monteiro , Marta Guimarães","doi":"10.1016/j.orcp.2025.01.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Conversional surgery following sleeve gastrectomy (SG) is required in about 20 % of patients due to suboptimal outcomes. Single anastomosis duodenoileal bypass (SADI) has emerged as an option for such cases, though long-term outcomes remain unclear. This review analyzed available data on SADI as a conversional or second-stage procedure after SG.</div></div><div><h3>Methods</h3><div>A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months’ follow-up up to July 2024.</div></div><div><h3>Results</h3><div>Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.</div></div><div><h3>Conclusion</h3><div>In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.</div></div>","PeriodicalId":19408,"journal":{"name":"Obesity research & clinical practice","volume":"19 1","pages":"Pages 1-10"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity research & clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871403X25000055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Conversional surgery following sleeve gastrectomy (SG) is required in about 20 % of patients due to suboptimal outcomes. Single anastomosis duodenoileal bypass (SADI) has emerged as an option for such cases, though long-term outcomes remain unclear. This review analyzed available data on SADI as a conversional or second-stage procedure after SG.

Methods

A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months’ follow-up up to July 2024.

Results

Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.

Conclusion

In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity research & clinical practice 医学-内分泌学与代谢

CiteScore

7.10

自引率

0.00%

发文量

审稿时长

49 days

期刊介绍： The aim of Obesity Research & Clinical Practice (ORCP) is to publish high quality clinical and basic research relating to the epidemiology, mechanism, complications and treatment of obesity and the complication of obesity. Studies relating to the Asia Oceania region are particularly welcome, given the increasing burden of obesity in Asia Pacific, compounded by specific regional population-based and genetic issues, and the devastating personal and economic consequences. The journal aims to expose health care practitioners, clinical researchers, basic scientists, epidemiologists, and public health officials in the region to all areas of obesity research and practice. In addition to original research the ORCP publishes reviews, patient reports, short communications, and letters to the editor (including comments on published papers). The proceedings and abstracts of the Annual Meeting of the Asia Oceania Association for the Study of Obesity is published as a supplement each year.